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GRANT FOR CANCER STUDY 
3-6-74 
State + cs + 
Dr. Carl L. Larson, director of the Stel Ia Duncan Memorial Research Institute at 
the University of Montana, has received a $13,480 grant from the National Cancer Institute 
to study the antigens of BCG responsible for immunizing and treating a form of lung cancer. 
"Baci I Ius Calmette-Guerin (BCG), is a vaccine commonty used to protect agalnst 
tuberculosis and leprosy. However, this tubercle bacteria is capable of ellclting broad 
non-specific resistance, meaning that it is helpful in building resistance against many 
diseases, including the lung cancer we are studying," satd Dr, Laison. 
"Mice injected with BCG two weeks before the lnjectton of tumor eel Is developed only 
62 lung tumors each compared with 126 tumors developed by mice not immunized with BCG. 
Even more dramatic, mice given the injection of BCG mixed with tumor eel Is developed only 
II tumors," added Dr. Larson. 
"However, repeated injection of viable (alive) BCG may cause severe skin reactions. 
We, therefore, need a better means of tapping BCG's immunogenic capabi I ities. 
"If we can fractionate (break down) and isolate the antigen responsible for the 
immunogenic effect of BCG, it then would be possible to develop a BCG booster program," 
said Larson. 
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